Retatrutide FDA approval is one of the most-searched questions in the GLP-1 world right now, and for good reason: Eli Lilly’s experimental “triple agonist” produced the largest weight loss ever recorded in a Phase 3 obesity trial. But a headline number is not the same as a prescription. Here is where the timeline actually stands as of September 2026, who can get early access today, and what to expect if you are already on Ozempic, Wegovy, Mounjaro, or Zepbound and wondering whether to wait.
What retatrutide is (and why it is different)
Retatrutide is a once-weekly injection that activates three hormone receptors at once: GLP-1, GIP, and glucagon. Semaglutide (Ozempic, Wegovy) hits one of those receptors. Tirzepatide (Mounjaro, Zepbound) hits two. Adding glucagon appears to boost energy expenditure on top of appetite suppression, which is why researchers expected bigger results. If some of those terms are new to you, our GLP-1 terminology guide covers agonists, incretins, and titration in plain English.
The key point: retatrutide is still investigational. It is not FDA-approved, it is not sold at pharmacies, and any “retatrutide” offered online today is not the real, tested product.
Retatrutide FDA approval timeline: the realistic dates
On July 23, 2026, Lilly said it plans to submit its application to the FDA in the first quarter of 2027. Standard FDA review of a new drug application typically runs 10 to 12 months, so the most realistic window for a decision is late 2027 to early 2028. A priority review could shorten that, but Lilly has not announced one.
A few milestones to watch along the way:
- Late 2026: Full TRIUMPH-1 data in a peer-reviewed journal, plus results from TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (established cardiovascular disease).
- Q1 2027: Lilly files with the FDA.
- Late 2027 to early 2028: Earliest plausible retatrutide FDA approval and launch, followed by the usual insurance-coverage lag of several months.
In other words, even in the best case you are looking at more than a year before retatrutide is something your doctor can prescribe.
What the Phase 3 results actually showed
The TRIUMPH-1 trial enrolled 2,339 adults with obesity or overweight (without diabetes) and followed them for 80 weeks. According to the topline results summarized by AJMC:
- 12 mg weekly: average loss of 70.3 lb (28.3%) at 80 weeks; 45.3% of participants lost 30% or more of their body weight.
- 9 mg weekly: average loss of 64.4 lb (25.9%).
- 4 mg weekly: average loss of 47.2 lb (19.0%), with only a single dose step up from the 2 mg starting dose.
- Placebo: about 3.9%.
A blinded extension to 104 weeks in people with a starting BMI of 35 or higher reached an average of 30.3% weight loss, a level historically associated with bariatric surgery. Participants also saw improvements in waist circumference, blood pressure, triglycerides, and inflammation markers. For comparison, the highest doses of tirzepatide and semaglutide land around 18% and 14% respectively in similar populations. You can see how those existing medications might play out for you with our free GLP-1 weight loss calculator.
Side effects look familiar, but the top dose is tougher
The safety profile matched other incretin drugs, with stomach-related symptoms leading the list. At the 12 mg dose, 42.4% of participants reported nausea, 32.0% diarrhea, 26.1% constipation, and 25.3% vomiting. Dropouts due to side effects rose with dose: 4.1% at 4 mg (lower than placebo), 6.9% at 9 mg, and 11.3% at 12 mg. Some participants also reported tingling or altered skin sensation (dysesthesia), most of which resolved during treatment. If you are already managing these symptoms on a current medication, our guides on reducing GLP-1 nausea and GLP-1 diarrhea apply to any drug in this class.
Retatrutide early access: who qualifies right now
On August 3, 2026, after weeks of pressure from physicians, Lilly opened a narrow pre-approval expanded access program. It is not a waitlist or a beta. To qualify, a patient must:
- Be at least 18 years old.
- Have refractory obesity despite tolerating the highest approved dose of an existing obesity medication.
- Live with at least two serious or life-threatening obesity-related complications that are already under medical care.
- Be unable to enroll in an ongoing retatrutide clinical trial.
- Have reviewed all standard treatment options with their doctor.
Applications go through a treating physician, not directly from patients, and Lilly reviews each case individually. For most people on a GLP-1 today, the practical path to retatrutide is still FDA approval, not expanded access.
Should you wait for retatrutide FDA approval?
Probably not, and most clinicians say the same. Here is why:
- Time: A year or more of untreated or under-treated weight is a real health cost, and the medications available today already deliver 15% to 20% average loss.
- Uncertainty: Filings can slip, the FDA can ask for more data, and launch pricing and insurance coverage are unknown.
- Switching later is normal: People move from semaglutide to tirzepatide all the time. If retatrutide arrives and makes sense for you, your provider can plan a transition then.
What you can do now is build the habits and the records that make any future switch easier: consistent weekly dosing, a clear side-effect history, and a weight trend your provider can read at a glance. You can track all of that free with Pep, which supports every current GLP-1 injection and pill plus custom medications, so a new drug can be logged the day it launches. If you want to see how tracking makes a difference, start with our free GLP-1 tracker guide.
What retatrutide might cost
Lilly has not announced pricing. For context, Zepbound currently runs $299 to $449 per month through LillyDirect self-pay vials and pens, and most new obesity drugs launch at or above the price of the products they compete with. Our GLP-1 cost guide tracks current prices for every approved option and will be updated when retatrutide pricing is public.
Retatrutide FDA approval: FAQ
When will retatrutide be FDA approved?
Lilly plans to file in the first quarter of 2027. With a standard review, retatrutide FDA approval would most likely come in late 2027 or early 2028. No date is guaranteed.
Can I get retatrutide before FDA approval?
Only through a clinical trial or Lilly’s expanded access program, which is limited to adults with treatment-resistant obesity and at least two serious obesity-related complications. Products sold online as “retatrutide” are not the tested medication.
How much weight do people lose on retatrutide?
In TRIUMPH-1, the 12 mg dose produced an average 28.3% loss at 80 weeks and 30.3% at 104 weeks in people with a higher starting BMI. The 4 mg dose averaged 19.0%. Individual results vary, and side effects increase at higher doses.
Download Pep free — track your shots, pills & progress in one app.
This article is for educational purposes only and is not medical advice. Talk with your healthcare provider about any medication decision.